Kevin Gilmour, DO
Pulmonary Disease · Hammonton, NJNPI 1275540106
Payments from drug & device makers
Across 380 payments — averaging $14.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- AstraZeneca$572
- Actelion Pharmaceuticals US, Inc.$539
- Philips North America LLC$411
- United Therapeutics Corporation$376
- Sanofi$340
- plus $2K from 23 others
What the payments were for
- Food & beverage$5,28796%
- Education$2204%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 107 | $1,313 |
| AstraZeneca | 40 | $572 |
| Actelion Pharmaceuticals US, Inc. | 29 | $539 |
| Philips North America LLC | 26 | $411 |
| United Therapeutics Corporation | 26 | $376 |
| Sanofi | 23 | $340 |
| Regeneron Healthcare Solutions, Inc. | 20 | $307 |
| Boehringer Ingelheim | 19 | $279 |
| Grifols USA, LLC | 16 | $224 |
| Insmed, Inc. | 14 | $222 |
| Genentech USA, Inc. | 10 | $166 |
| Mylan Specialty L.p. | 8 | $117 |
| Amgen | 7 | $116 |
| Sanofi-aventis U.S. LLC | 1 | $79 |
| Verona Pharma, Inc. | 4 | $71 |
| Mallinckrodt Hospital Products Inc. | 5 | $71 |
| Electromed, Inc. | 6 | $47 |
| Gilead | 4 | $46 |
| Viatris Specialty LLC | 2 | $32 |
| Merck | 2 | $29 |
| Novartis | 2 | $27 |
| Sunovion Pharmaceuticals Inc. | 2 | $22 |
| ANI Pharmaceuticals, Inc. | 1 | $16 |
| Vifor Pharma, Inc. | 1 | $16 |
| Jazz Pharmaceuticals Inc. | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Bayer | 1 | $14 |
| Harmony Biosciences LLC | 1 | $14 |
| Mallinckrodt Enterprises LLC | 1 | $12 |
How this compares
$5,507 in reported general payments places this provider in the 70th percentile of 472 pulmonary disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 272 | $381,407 |
| OfevNintedanib Esylate | 23 | $298,369 |
| OpsumitMacitentan | 18 | $227,223 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 65 | $59,443 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 54 | $45,346 |
| EliquisApixaban | 37 | $42,783 |
| Breo ElliptaFluticasone/Vilanterol | 46 | $39,410 |
| Spiriva RespimatTiotropium Bromide | 27 | $35,009 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 37 | $32,948 |
| XareltoRivaroxaban | 26 | $28,091 |
| Bosentan | 12 | $14,807 |
| Spiriva HandihalerTiotropium Bromide | 15 | $14,149 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 296 | $13,988 |
| Advair HfaFluticasone Propion/Salmeterol | 23 | $11,829 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 60 | $11,384 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $1,313 | $469,994383 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $279 | $366,32687 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit, Bosentan | $539 | $242,03030 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $572 | $66,60781 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 472 pulmonary disease providers in New Jersey.
Other pulmonary disease in Hammonton
- Reynold PanettieriNew Brunswick$2.5M
- Vinay SikandToms River$1.8M
- Stanley FielMorristown$1.3M
- Joseph HoffmanPark Ridge$1.1M
- Robert SussmanSummit$645K
- Ronaldo GoHackensack$563K
- Deborah GossHackensack$558K
- Sabina HussainNew Brunswick$555K
- Manuel CunananMillville$489K
- Emanuele SantomauroHackensack$420K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.